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Abstract: Lung cancer is the leading cause of death in men and women worldwide, affecting millions
of people. Between the two types of lung cancers, non-small cell lung cancer (NSCLC) is more
common than small cell lung cancer (SCLC). Besides surgery and radiotherapy, chemotherapy
is the most important method of treatment for lung cancer. Indole scaffold is considered one of
the most privileged scaffolds in heterocyclic chemistry. Indole may serve as an effective probe
for the development of new drug candidates against challenging diseases, including lung cancer.
In this review, we will focus on discussing the existing indole based pharmacophores in the clinical
and pre-clinical stages of development against lung cancer, along with the synthesis of some of
the selected anti-lung cancer drugs. Moreover, the basic mechanism of action underlying indole
based anti-lung cancer treatment, such as protein kinase inhibition, histone deacetylase inhibition,
DNA topoisomerase inhibition, and tubulin inhibition will also be discussed.
Keywords: lung cancer; indole; non-small cell lung cancer; kinase inhibition; apoptosis; DNA
topoisomerase, histone deacetylase inhibition
1. Introduction
Lung cancer remains the deadliest disease on record, with approximately 2.09 million new cases
reported each year. According to the World Health Organization, it is responsible for 1.7 million cancer
deaths worldwide per year [1]. There are two major types of lung cancer: small cell lung cancer (SCLC)
and non-small cell lung cancer (NSCLC). Among these two types of lung cancers, NSCLC is responsible
for approximately 80%–90% of cancerous tumors [2,3]. NSCLC is further divided into three major
histological subtypes: squamous-cell carcinoma, adenocarcinoma, and large-cell carcinoma. SCLC and
squamous-cell carcinoma are strongly linked to smoking, while adenocarcinoma is the most common
type of lung cancer in patients who have never smoked [4].
Treatment of lung cancer is commonly addressed by surgical removal of the affected area and
by chemotherapy, which applies a combination of one or more drugs in conjunction with radiation
therapy. However, multidrug resistance and the severe side effects associated with chemotherapy
persists as one of the major challenges in the treatment of lung cancer.
1.1. Indole and its Pharmacological Significance
Indole is a pervasive and naturally occurring heterocyclic compound, the structure of which
comprises of a six-membered benzene ring tethered to a five-membered pyrrole ring [5] (Figure 1).
With its 10 π-electrons, indole follows Huckel’s rule of aromaticity. It is more prone to electrophilic
substitution reactions similar to the benzene ring. Molecular orbital studies showed that the 3-position
of indole is more reactive towards the electrophilic substitution reactions. Indoles can undergo
N-substitution reactions under basic conditions owing to the slightly acidic nature of the—NH bond in
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indole [6]. The first synthesis of indole was accomplished in 1866 by Adolf von Baeyer [7]. Due to the
diverse applications of the indole scaffold in both the biological and pharmacological fields, hundreds
of synthetic schemes were published. The most prominent and widely used ones are those reported by
Fisher [8], Bischler [9], Hemetsberger [10], Nenitzescu [11], Bartoli [12], and others [13,14].
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Serotonin (5-hydroxytryptamine) is an important neurotransmitter associated with the 
transmission of nerve impulses. It further serves as a precursor to melatonin, a neuro-hormone 
secreted by the pineal gland. Besides, melatonin is involved in several physiological processes 
beyond the circadian rhythm [19,20]. Indole-3-acetic acid is the most common and widely studied 
plant hormones of the auxin class (Figure 2) [21]. It is also the normal urinary tryptophan metabolite 
observed to be elevated in patients with various forms of liver disease [22]. 
1.3. Significance of Indole Based Drugs 
Delavirdine is an indole based anti-retroviral drug approved by the Food and Drug 
Administration (FDA) in 1997 for the treatment of HIV patients (Figure 3). The drug acts as a non-
nucleoside reverse transcriptase inhibitor and an inhibitor of the cytochrome P450 enzyme CYP3A4 
[23]. Reserpine is a known indole alkaloid derived from the Rauwolfia serpentina plant. It has been 
utilized as an anti-psychotic and anti-hypertensive agent to treat high blood pressure [24]. 
Panobinostat is an oral histone deacetylase inhibitor developed by Novartis and approved to treat 
multiple myeloma. The drug is currently in phase II trials to treat acute myeloid leukemia [25] and 
phase I and II clinical trials for the treatment of AIDS [26]. Zafirlukast is the first orally active indole-
like leukotriene-receptor antagonist approved by the FDA to treat asthma (Figure 3) [27]. It is mostly 
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Owing to its bioavailability and pharmacological applications, indole is considered the most
privileged scaffold in heterocyclic chemistry with such widespread applications as antiviral,
antimicrobi l, anti-inflammatory, anti-cancer, anti-hypertensive, anti-diabetic, and antioxidant [15–17].
1.2. Natural Abundance of Indoles
Naturally occurring indole derivatives, such as glucobrassicin and indole-3-carbinol, are commonly
found in cruciferous vegetables like cabbage, broccoli, and sprouts [18]. Indole-3-carbinol and its
dimeric product 3,3′-diindolylmethane have been found to induce apoptosis in cancer cells [18]. This is
a property that has increasingly commanded the attention of researchers from around the world. To get
the greatest benefits, indole rich sources belonging to the Brassica family are particularly recommended
by the National Cancer Institute to reduce the risk of cancer [18].
Tryptophan containing indole is an essential amino acid found in many natural resources. It is
also a biosynthetic precursor for the tryptamine, 5-hydroxy-tryptophan, an immediate precursor of
serotonin (Figure 2).
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Delavirdine is an indole based anti-retroviral drug approved by the Food and Drug 
Administration (FDA) in 1997 for the treatment of HIV patients (Figure 3). The drug acts as a non-
nucleoside reverse transcriptase inhibitor and an inhibitor of the cytochrome P450 enzyme CYP3A4 
[23]. Reserpine is a known indole alkaloid derived from the Rauwolfia serpentina plant. It has been 
utilized as an anti-psychotic and anti-hypertensive agent to treat high blood pressure [24]. 
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Serotonin (5-hydroxytryptamine) is an important neurotransmitter associate with the
transmission of nerve impulses. It further serves as a precursor to mel tonin, a neuro-hormone
secreted by the pineal gla d. Besides, melatonin is involved in several physiological processes beyond
the circadian rhythm [19,20]. Indole-3-acetic acid is the most common and widely studied plant
hormones of the auxin class (Figure 2) [21]. It is also the normal urinary tryptophan metabolite
observed to be elevated in patients with various forms of liver disease [22].
1.3. Significance of Indole Based Drugs
D lavirdine is an indole based anti-retroviral drug approv d by the Food and Drug Administratio
(FDA) in 1997 for the treatment of HIV patients (Figur 3). The drug acts as a non-nucleoside verse
tr scriptase nhibitor and a inhibitor of the cyt chrome P450 enzyme CYP3A4 [23]. Reserpine
is a known indole alkaloid derived from the Rauwolfia serpentina plant. It has be n util zed as an
anti-psychotic a d nti-hype tensive ag to treat high blood pressure [24]. P nobinostat is an
oral histone deac tylase inhibitor developed by Novartis and approved to treat multiple myel ma.
The drug is currently in phase II trials to treat acute myeloid leukemia [25] and phase I and II clinical
trials for the treatment of AIDS [26]. Zafirlukast is the first orally active indole-like leukotriene-receptor
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antagonist approved by the FDA to treat asthma (Figure 3) [27]. It is mostly used in combination with
an inhaled steroid and/or long-acting bronchodilator. Tadalafil is another indole based drug approved
for the treatment of erectile dysfunction in men [28]. Pindolol is an antagonist of the serotonin 5-HT1A
receptor and it is used to treat hypertension and as an anti-depression agent [29,30]. Indomethacin is a
non-steroidal anti-inflammatory drug applied to the treatment of severe osteoarthritis, rheumatoid
arthritis, gouty arthritis, and ankylosing spondylitis [31] (Figure 3).
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Figure 3. Indole scaffold in Food a i istration (FDA) a proved drugs.
1.4. Methodology for Bibliographic Search
We used the foll wing datab ses to survey the literature porting indole scaffold usages for lung
cancer in in vitro and in vivo models:
1. Scifinder website at https://scifinder.cas.org/.
2. PubMed website at https://www.ncbi.nl .ni . / /.
In addition, we filtered the available articles based on the following criteria:
a. Articles must have chemical structures of indoles.
b. Articles must have biology data of indoles.
c. We included articles with bioactivity data of indoles specifically in lung cancer.
d. We excluded articles with bioactivity data of indoles other than lung cancer.
2. Indole Derivatives as Anti-Lung Cancer Agents
Indole based alkaloids share great historical popularity as anti-cancer drugs. The most prominent
among them have been vincristine, vinblastine, vinflunine, and vinorelbine derived from the plant
Catharanthus roseus [32] (Figure 4). With over 150 alkaloids, C. roseus is the most well-studied medicinal
plant. Vinorelbine is the most commonly used drug to treat lung cancer and vinblastine in combination
with cisplatin is used in the treatment of NSCLC [33]. The anti-cancer activity of these derivatives
was attributed to their ability to dissolve the mitotic spindles and cell division resulting from the
microtubule disruption [33].
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e otency of indoles as anti-cancer agents is exemplified by (i) various indole derivatives, such as
indole-3-carbinol, indole-3-carboxaldehyde; (ii) functionalized indoles, such as diaryl-indoles, indolyl
chalcones, indolyl azoles, and (iii) bisindole derivatives [39]. Several studies c st light on the anti-cancer
efficacy of indole derivatives [40–43]. Besides, several reviews were submitted in recent years exploring
the biological and pharmacological applicati ns of indole derivatives as anticancer agents [39,44–47].
Though many comprehensive reviews wer published, focusing on indole d rivatives as anti-cancer
agents, so far to our knowledge, there are n reports specifically focused n the efficacy of indole-base
compounds in c mbatting lung cancer. Therefore, we are seeking to fill this gap by pr senting a brief
review focused on the development of indole-based d rivatives as anti-lung cancer ag nts. In this
paper, we included work between 2000 and 2019, of indol -bas d derivatives in the clinical n
subclinical stages of development to combat lung cancer. As it is not p ssible to include the synthesis
of all indole base anti-lung cancer agents, we are reporting herein the synthesis of som of the select d
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derivatives. We apologize in advance for possible neglect of any relevant work including synthesis on
the subject. Basic mechanisms by which indole derivatives exhibit anti-lung cancer properties involve
the induction of apoptosis, microtubule inhibition, protein kinase inhibition, histone deacetylase
inhibition, and DNA topoisomerase inhibition (Figure 5). In the following sections, we will discuss
several derivatives of indoles, developed and understudy for their prospective use against lung cancer,
along with their mechanism and synthesis of some of the selected derivatives.
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signaling pathways downstream of tyrosine kinases and dysregulation of these signaling pathways
h s been observed i several human cancers. Bec use of the biological roles of Akt sign ling pathways,
everal categories of inhibitors tar eting these kinase were developed for NSCLC treatment [53,54].
Nesi t al. designed and synthesized a novel set of 2-oxindole-derivatives ((6a–c), (OXIDs))
targeting serine/threonine kinases, 3-phosphoinositide-dependent protein kinase-1 and/or Akt
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2.3. Epidermal Growth Factor (EGFR) Inhibition
Osimertinib (AZD9291, 16a) is an FDA-approved drug to treat non-small lung cancer as an EGFR
inhibitor [36]. However, AZD9291 showed low specificity to EGFR along with severe side effects
and cardiotoxicity at high doses (Scheme 2). A structure-activity relationship study of AZD9291
reported by Zhao et al. showed that the fluorinated analog (17, Figure 6) improved selectivity towards
EGFRT790M/L858R double mutants with IC50 as low as 8 nM and a 200-fold increase in the selectivity
towards wild type EGFR. It was theorized that the fluorinated indole (17) plays an important role
in enhancing the binding interaction with T790M active binding domain of EGFR and reducing the
demethylation ability of the indole ring, which in turn, can enhance the anti-metabolism ability of
AZD9291 derivatives. The fluorinated derivative of AZD9291 (17), however, resulted in the loss of
kinase activity. Next, the authors designed compound 16b by the aid of molecular docking studies
to obtain an optimized derivative without fluorine substitution. They showed that 16b can serve
as a potent EGFRT790M/L858R inhibitor [56]. The synthesis of compounds 16a and 16b is shown in
Scheme 2 [56,57].
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The first step of the synthesis involved the methylation of indole (7) using methyl iodide and
sodiu hydride to furnish the methylated indole (8). A ixture of the 2,4-dichloro-pyri idine (9a)
or 2,4-dichloro-6- ethyl-pyri idine (9b) in dimethoxyethane and AlCl3 ith 1- ethylindole (8)
yielded compound 10a or 10b respectively. A nucleophilic aromatic substitution reaction between
the amino compound 11 and the chloro pyrimidine 10a/10b in generated the fluoro intermediate
(12a/12b). The reaction of the fluoro compounds (12a/12b) with N,N,N-trimethylethane-l,2-diamine
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in diisopropylethylamine and dimethylacetamide gave the nitro intermediates 13a/13b, which was
subsequently reduced to the amines 14a/14b. The latter amines were treated with acryloyl chloride to
afford the desired final products (16a/16b) (Scheme 2).
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2.4. Anaplastic Lymphoma Kinase Inhibition
Anaplastic lymphoma kinase (ALK) belongs to the family of tyrosine kinases and is regarded as a
potential target for the treatment of neuroblastomas as ALK gene mutations and overexpression is
frequently observed in neuroblastoma patients. AZD3463 is an ALK inhibitor designed by Astrazeneca
to overcome the acquired resistance towards crizotinib (Figure 6). Crizotinib is an FDA-approved drug
for the treatment of NSCLC [58]. It is further known to be a potent second-generation ALK (anaplastic
lymphoma kinase) inhibitor, which proved effective against a broad spectrum of ALK rearrangements
and ALK mutations [59].
Alectinib, as mentioned earlier, is an FDA approved drug for the treatment of NSCLC (Scheme 3).
It is a highly selective and potent ALK inhibitor. Synthesis of alectinib was accomplished in eight steps,
as shown in Scheme 3 [60,61].
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Scheme 3. Synthesis of alectinib adapted from the references [60,61].
The bromination of compound 18 with N-bromosuccinimide, followed by the Fischer indole
synthesis, resulted in the regioisomeric mixture (1:1, 1-CN- and 3-CN-derivatives) of compound
20. The desired isomer was isolated and the 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ)
oxidation was conducted, resulting in the ketone 21. Demethylation of compound 21 with pyridinium
hydrochloride generated the alcohol (22). The resulting alcohol (22) was then triflated and then reacted
with 4-morpholinopiperidine to provide the bromo compound (24). The bromo intermediate (24) was
then subjected to Sonogashira coupling with acetylene, followed by hydrogenation of the terminal
alkyne generated the desired compound (alectinib), as shown in Scheme 3.
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2.5. Protein Kinase C Inhibition
Protein kinase C (PKC) is a family of structurally related serine-threonine kinases that can be
activated by G-protein coupled receptors [62]. PKC is implicated in several cellular functions and the
regulation of survival signals in various cell types and, therefore, PKC has become a drug target for
the development of anti-cancer drugs. The activation of PKC by various oncogenes can lead to the
malignant transformation and abnormal expression of PKC isoforms, as detected in the head, neck,
and other types of cancers.
Enzastaurin is a popular anti-tumor agent, which showed promising results with T-cell and B-cell
lymphoma, multiple myeloma and other solid tumor malignancies (Scheme 4). Enzastaurin is a potent
inhibitor of PKC and PI3K/AKT pathway. It is found to effectively inhibit tumor cell growth in both
in vitro and mouse xenograft models [63]. Nakajima and his team showed that enzastaurin displayed
cell growth inhibition with IC50 of 3–10 µmol/L, as exhibited in a panel of both SCLC and NSCLC cell
lines [64,65]. Besides, they found that enzastaurin can suppress tumor-induced angiogenesis in A549
NSCLC xenografts [66]. The drug is undergoing clinical trials to evaluate its efficacy in the treatment
of NSCLC and several other types of cancers [67].
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tivantinib and erlotinib can enhance treatment efficacy in patients with previously treated, EGFR 
mutant, non-squamous NSCLC, as compared to erlotinib alone [69]. 
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The synthesis of enzastaurin is shown in Scheme 4 [65]. Briefly, the reduction of indole-3-acetamide
(26) with BH3.pyridine gave the indolin-3-acetamide (27) followed by reductive amination with the
ketone (28) resulted in the intermediate 29. Compound 30 was obtained by oxidation of compound 29
using DDQ. On the other hand, the indole-3-glyoxylate ester (32) was synthesized from 1-methylindole
(31) and oxalyl chloride. Finally, condensation of the amide intermediate (30) with indole-3-glyoxylate
ester (32) in the presence of a base generated enzastaurin [67] (Scheme 4).
2.6. GSK Inhibition
Tivantinib is an oral, selective indole based small molecule MET inhibitor, being evaluated in
advanced clinical trials for the treatment of NSCLC (Scheme 5). Early reports showed that tivantinib is a
potent and highly selective inhibitor of receptor tyrosine kinase (cMET). However, further investigation
led by Rix et al. revealed glycogen synthetase kinase (GSK)3α and GSK3β to be novel tivantinib
targets. In their detailed study of mechanism, they found that tivantinib acts by the simultaneous
inhibition of GSK3α and GSK3β leading to apoptosis in lung cancer cells [68]. Their experiments
demonstrated that (−)-tivantinib was more potent than (+)-tivantinib in the inhibition of GSK3α
and GSK3β. The latest investigation by Scagliotti et al. has shown that a combination of tivantinib
and erlotinib can enhance treatment efficacy in patients with previously treated, EGFR mutant,
non-squamous NSCLC, as compared to erlotinib alone [69].
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The synthesis of tivantinib is shown in Scheme 5 [69,70]. The reaction of the tetrahydroquinoline
(33) with the bromo-ethylpyruvate yielded the ketoester 34, which was transformed to the ester
indole 35 under anhydrous magnesium chloride treatment. Ester 35 was hydrolyzed to carboxylic
acid intermediate 36 followed by decarboxylation reaction using copper chromite and quinoline
afforded the indole 37, which was treated with oxalyl chloride and methanol to obtain the ketoester
38. Condensation of the ketoester 38 and indole-3-acetamide (26) generated the intermediate 39 as
a racemic mixture of tivantinib. Preparative chiral HPLC purification yielded two optically pure
diastereoisomers of (3R, 4R) (−)-tivantinib and (3S, 4S) (+)-tivantinib (Scheme 5).
2.7. Inhibition of Multiple Receptor Kinases
Anlotinib is a novel inhibitor targeting multiple receptor tyrosine kinases, namely vascular
endothelial growth factor receptor type 2 and 3 (VEGF 2 and 3), the platelet-derived growth factor b
(PDGFb), and the fibroblast growth factor 2 (FGF-2) [71] (Figure 4). Studies revealed that VEGF is a
critical growth factor in tumor angiogenesis. Along with PDGF and FGF-2, it stimulates proliferation,
migration, survival, and new vessel formation of endothelial cells in tumors. Studies showed that
inhibition of these angiogenic receptor tyrosine kinases can be very effective in the treatment of tumors.
Notably, the inhibitory effect of anlotinib was much more pronounced than with sunitinib, sorafenib,
and nintedanib suggesting it as a potent anti-lung cancer drug. Anlotinib has emerged as a potential
third-line treatment in advanced NSCLC patients [72].
Nintedanib is an oral, small molecule multiple kinase inhibitor (Figure 4). This drug in combination
with docetaxel was approved worldwide for the treatment of NSCLC [73]. It functions as a tyrosine
kinase inhibitor targeting three angiokinase inhibitors including VEGF (1–3), PDGF receptors (α/β)
and fibroblast growth factors (1–3). Both in vitro and in vivo studies in human NSCLC xenografts
have confirmed that by the inhibition of both AKT and mitogen-activated protein kinases signaling
pathways, nintedanib resulted in the inhibition of cell proliferation, apoptosis in endothelial cells, and
the cell types involved in angiogenesis [74].
2.8. Tubulin Inhibition
Tubulin is a globular protein comprising α and β-heterodimers, which polymerize to form the
biopolymers of microtubules. Being the third major component of the cytoskeleton, microtubules
play a critical role in cell division, in addition to aiding in both inter and intra-cellular movement and
maintaining cell shape [75]. As microtubules play a key role in cell division, they are attractive targets
for the development of anti-cancer agents.
Tubulin inhibitors interfere with the polymerization and depolymerization of the microtubules.
They are categorized as either tubulin stabilizing agents or destabilizing agents (Figure 7). While the
tubulin stabilizing agents ultimately lead to the polymerization of microtubules by inhibiting
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depolymerization, the destabilizing agents function by inhibiting polymerization, thereby shortening
the microtubules [76]. The indole based alkaloids and their derivatives, such as vincristine, vinblastine,
vinorelbine, vinflunine, vindesine belong to the class of polymerization inhibitors that bind to the
β-subunit of tubulin at a distinct region called as the vinca-binding site, as shown in Figure 7 [76].
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Vinorelbine is a semi-synthetic indole base al l i . It is
a known microtubule inhibitor with selectivity towards mitotic microtubules. It disrupts he
mitotic spindle formation and ul imately prevents cell division. Vinorelbine is se i combination
chemotherapy with cisplatin and cetuximab to treat NSCLC [7 ]. Besides vinorelbine, vinflunine was
also shown to have the potential to treat the NSCLC in the adjuvant chemotherapy with platinum-based
drugs (Fig re 4) [78]. Among the other counterparts, such as vincristine, vinbla and vinorelbine,
vinflunine is found to have higher activities in vivo w th low drug resistance. Therefore, vinflunine
has evolved to b a more pot nt drug in lung cancer treatme t [33].
Cong et al. reported an indole-chalcone derivative (FC7 , Scheme 6) that can ar est cancer cell
growth by binding to tubulin, exhibiting a similar mechanism of action as colchicine. FC7 exhibited
a potent gro th i ajority of NCI-60 human cancer ce l lines with GI50 ~ 6 µM [79].
The ability of FC77 to retain its cyt tox city against multi-drug resistant li ( ith nanomolar
GI values) and low cytotoxicity levels towards normal mobilized peripheral blo d cells revealed that
FC7 may be a potential therapeutic agent in treating multi-drug resistant cancers such as NSCLC.
Moreover, the direct interaction of FC7 with tubulin and inhibition of microtubule dynamics with
IC50 values of 3 n compared to popular drugs such as paclitaxel and vincristine with IC50 values of
14 nM and 37 nM, respectively, makes it an attractive microtub le-targeting a ent for the tr atment of
multidrug-resistant can ers [79].
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The synthesis of FC77 was accomplished in a single step, as shown in Scheme 6 [79].
The condensation reaction between the acetophenone derivative (40) with the indole-3-carboxaldehyde
(41) in the presence of piperidine afforded the target compound (FC77).
Das et al. recently synthesized a series of six bis(indolyl)-hydrazide−hydrazones (NMK-BH
compounds), in order to develop novel and efficient microtubule-targeting chemotherapeutic agents
against lung cancer. They achieved this by linking the two indole rings with an active pharmacophore
linker, as shown in Scheme 7. Cytotoxicity studies of these compounds against human lung
adenocarcinoma A-549 cells revealed that NMK-BH3 with the electron-donating 5-OMe group and
the indole rings tethered to the C-2 position of the indole-A was found to be more potent than other
combinations. The mechanism of action of NMK-BH3 in NSCLC (A549 cells) revealed the disruption
of the mitotic spindle and depolymerization of the interphase microtubule network ultimately led to
apoptotic cell death. This is signified by the overexpression of Bax, p53, caspase 3, and caspase 9 and
decrease in the Bcl-2 expression [80]. Their experiments revealed that NMK-BH3 was more sensitive
to human lung adenocarcinoma A549 cells with IC50 of ~2 µM, while highly resistant to normal human
lung fibroblasts (WI38) with IC50 of 48.5 µM (24 fold).
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Sche e 7. t i f - a te fro the reference [80].
The synthesis of N K-BH3 was achieved as shown in Scheme 7 [80]. A solution of indole-2-
carboxylic acid (42) was refluxed in ethanol with a catalytic amount of dilute sulfuric acid, to obtain
the corresponding ethyl ester intermediate, which was treated with hydrazine hydrate to obtain the
intermediate 43. On the other hand, the preparation of the indole-3-carboxaldehyde 45, via treatment
of the methoxy indole 44 with phosphorous oxychloride and anhydrous D F. Finally, condensation
of hydrazide inter ediate 43 and indole-3-carboxaldehyde 45 in the presence of a catalytic a ount
of glacial acetic acid, and the ixture was refluxed at 80 ◦C for 5 h. The resulting ixture was then
cooled to collect the desired target (N K-BH3).
2.9. Inhibition of DNA-Topoisomerases
Owing to the drug resistance and acute toxicity associated with lung cancer treatment,
the combination of two or more pharmacophores has become an attractive strategy in drug discovery
and has evolved as an effective tool in treating lung cancer patients. To overcome the multi-drug
resistance in NSCLC patients, Chen et al. adapted the above strategy and developed hybrid molecules to
improve drug efficacy. They designed and synthesized a series of indolizino[6,7-b]indoles, incorporating
two pharmacophores: β-carboline group and a bis(hydroxymethyl)pyrrole group with topoisomerase
(Topo) I/II inhibition and DNA cross-linking abilities respectively [81,82] (Figure 8). The hybrid
derivative (BO-1978) was found to be effective in the suppression of lung adenocarcinoma A549 cells
through the inhibition of Topo I/II and the induction of DNA cross-links resulting in DNA damage
and a resulting cell cycle arrest. The hybrid derivative (BO-1978) was synthesized as shown in
Scheme 8 [81,82].
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Figure 8. Biological significance of bis(hydroxymethyl)pyrrole and β-carboline.Molecules 2019, 24, x FOR PEER REVIEW 12 of 26 
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Scheme 8. Synthesis of BO-1978 adapted from the references [81,82].
The tetrahydro-β-carboline 44 was synthesized by adding formaldehyde to L-tryptophan methyl
ester hydrochloride (43). The reaction of compound 44 with propionyl chloride in triethylamine
provided the amide (45). The nitrogen of the indole intermediate (45) was methylated using
sodium hydride and methyl iodide to generate the compound 46. The reaction of 46 with dimethyl
acetylenedicarboxylate (DMAD) in acetic anhydride yielded the diester 47, which was further reduced
with lithium aluminum hydride to afford the desired compound (BO-1978) (Scheme 8).
The hybrid derivative compound (BO-1978) showed the synergistic effect of both the
pharmacophores, which incorporates the anti-proliferative activity and Topo I and Topo II inhibition
of β-carboline and the potent anti-tumor activity of bis-hydroxy-methylpyrrole, which is known to
induce the DNA cross-linking (Figure 8).
In the same front, Chang et al. developed a series of novel indolizino[8,7-b]indole hybrids
(Figure 9) [83].
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Figure 9. esign of indolizino[6,7-b]indole and indolizino[8,7-b]indole derivatives.
As shown in Figure 8, the substituent on the indole nitrogen is found to play a key role in
determining the activity of the hybrid molecule. The presence of –Me group (53) makes them potent
DNA cross-linking agents, whereas –NH derivatives (52) are potent TOPO-II inhibitors. The resulting
co pounds were most sensitive to SCLC (H526) cells both in vitro and in vivo studies. One of the
compounds 52, was found to have potent Topo II inhibitory activity with significant tumor suppression
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in nude mice bearing SCLC H526 xenografts (Scheme 9). Compound 52 was shown to be more potent
than cisplatin and etoposide and possessed the comparable potency of irinotecan [83].Molecules 2019, 24, x FOR PEER REVIEW 13 of 26 
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The synthesis of co pounds 52 and 53 is sho n in Sche e 9 [83]. Briefly, the reaction of
trypta ine hydrochloride (48) ith an aqueous solution of glyoxalic acid and potassiu hydroxide
generated the tetrahydro-β-carboline inter ediate (49). o pound 50 as prepared by the addition
of acetyl chloride to 49, then as added to co pound 50 in acetic anhydride generated the
tetracyclic diesters (51). Finally, the reduction of 51 ith lithiu alu inu hydride afforded the
desired tetracyclic diol (52), hile the treat ent of inter ediate 51 ith sodiu hydride and ethyl
iodide resulted in desired - ethyl-tetracyclic diol (53).
In an attempt to develop effective Topo-II inhibitors as potent anti-cancer agents, Song et al.
synthesized a novel series of bisindolylalkanes analogs such as 3,3′-(thiochroman-4,4-diyl)
bis(1H-indole) and tested against a variety of human cancer cell lines (Scheme 10). Notable among
them, compounds 57(a-c) were found to be potent against A549 cells with IC50 values of ~9 µg/mL [84].
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c e e 10. Synthesis of co poun s 57(a–c) a a te fr refere ce [84].
The synthetic scheme of compounds 57(a–c) was shown in Scheme 10 [84]. The first step
involved the condensation of substituted benzene thiols 54(a–c) with 3-chloropropanoic acid and
sodium hydroxide in water, followed by treatment of corresponding intermediate 55(a–c) with
concentrated sulfuric acid to obtain the intermediates 56(a–c). A mixture of indole (7) and substituted
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thiochroman-4-ones 56(a–c), in the presence of silicotungstic acid was refluxed in ethanol yielded the
desired compounds (57(a–c)).
Makaluvamine is an indole based alkaloid metabolite isolated from a marine sponge Zyzzya.
This compound showed significant cytotoxic activity and DNA topoisomerase II inhibition [85].
Nadkarni et al. synthesized a series of makaluvamine analogs and studied their biological activities
against various human lung cancer cell lines (Scheme 11). One of the compounds (60) was found
to be most potent against human lung cancer cell lines of both human adenocarcinoma (A549) and
carcinoma (H1299) cells with IC50 of 0.3 and 0.58 µM, respectively. Further studies revealed that the
compound induced both apoptosis and S-phase cell cycle arrest [86].
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The synthesis of makaluvamine 60 is represented in Scheme 11 [86]. Compound 60 was
synthesized in one-step synthesis from the tricyclic compound 58. Condensation of compound
58 with 4-chloro-benzylamine (59) in anhydrous methanol followed by treatment with trifluoroacetic
acid (TFA) afforded the desired makaluvamine compound (60).
2.10. Histone Deacetylase (HDAC) Inhibitors
HDAC enzymes are involved in a variety of cellular processes such as cell proliferation, cell
differentiation, and apoptosis [87]. Research studies show that the dysregulation of HDAC can lead
to several types of tumor malignancies. HDAC inhibitors have, thus, evolved as a new class of
anti-cancer agents because of their efficacy to arrest cell growth, cell differentiation, and cell death
by apoptosis [88,89]. In this direction, Han et al. investigated the anti-cancer activity of A549 and
H441 lung cancer cells using two novel cyclic amide-bearing hydroxamic acid-based HDAC inhibitors
SL142 and SL325. Their studies revealed that both derivatives showed more potent cell growth
inhibition and cell death than the hydroxamic acid-based HDAC inhibitor suberoylanilide hydroxamic
acid (SAHA) (Figure 10). Besides, these compounds can also induce significant caspase activity and
subG0/G1 population in human epithelial (H441) and adenocarcinoma (A549) lung cancer cells, thereby
demonstrating that they are more effective than SAHA [90,91].
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A new class of 1-arylsulfonyl-5-N-hydroxyacrylamide indoles was reported by Lai et al., as potent
histone deacetylase inhibitors. Further investigation revealed that the lead compound 61 demonstrated
GI50 of 1 µM against the A549 cell lines. They demonstrated that the N-hydroxyacrylamide group
located at the C-5 position of indole ring was more potent than other derivatives. When the group
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tested the efficacy of the compounds on a human xenograft model in nude mice bearing A549 lung
cancer cell lines, compound 61 was found to be more effective than SAHA (Figure 10). The authors
found that there was a 47% tumor growth delay (32% tumor growth inhibition) by oral administration
with compound 61 daily at 200 mg/ kg showing its efficacy as a potential anti-lung cancer agent [92].
Dacinostat (NVPLAQ824) is an HDAC inhibitor introduced by Novartis in 2003 and is used as an
anti-cancer agent (Scheme 12) [93]. Dacinostat was found to inhibit an HDAC enzyme isolated from
H129 cell lysates with a potency of 32 nM and human lung cancer cells (H1299) with a potency of
150 nM, respectively. Besides, it was also found to be potent in the in vivo studies, in subject mice,
against human lung carcinoma (A549 and HCT116) sub-cutaneous xenografts. Detailed studies of the
mechanism of action showed that dacinostat acts on the A549 and HCT116 cells by G2-M arrest with a
significant sub-G1 population, showing that the cells were subjected to apoptosis [94–97].
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The synthesis of dacinostat is shown in the Scheme 12 [98]. Briefly, esterification of
4-formyl-cinnamic acid followed by reductive amination with tryptamine 48, generated the condensed
indole 64. The resulting intermediate 64 was alkylated with 2-(tert-butyldimethylsilyloxy-ethylbromide
(65) afforded the tertiary amine 66. The methyl ester of 66 was transformed to hydroxa ic acid 67,
followed by deprotection yielded the desired dacinostat (Scheme 12).
2.11. Miscellaneous Indole Derivatives in Anti-Lung Cancer Treatment
Lv et al. designed and synthesized a series of novel 1-(3-dimethyl-aminopropyl)indolin-2-one
derivatives. Here the most active derivative was found to be more potent than sunitinib against
NSCLC (A549) cells. These compounds were tested for their antiproliferative activity against lung
adenocarcinoma (A549) cells and they found that all the compounds showed potent activity. Among all
generated compounds, compound 77 (Scheme 13) proved to be most potent with IC50 of 1.10–1.47 µM,
which is 1.8–6 fold higher than sunitinib [99].
A representation of the synthesis of the most potent compound 77 is shown in Scheme 13 [99,100].
Briefly, the reaction of tert-butyl acetoacetate 68 with sodium nitrite in acetic acid generated the oxime
69. The resulting oxime (69) was reacted with ethyl acetoacetate and zinc powder in acetic acid yielded
the pyrrole diesters (70). Ester hydrolysis of 70, followed by monodecarboxylation reaction in the
presence of conc. HCl and ethanol yielded the ethyl ester 71. Then subsequent treatment of 71 with
phosphorus oxychloride yielded the aldehyde 72. The resulting intermediate (72) was hydrolyzed,
followed by amide bond formation in the presence of morpholine and coupling reagents (EDC/HOBt)
yielded compound 74. On the other hand, compound 76 was obtained through the treatment of
intermediate 75 with 3-chloro-N,N-dimethyl-propan-1-amine in the presence of KF-alumina. Finally,
Knoevenagel condensation of the intermediates 76 and 74, followed by HCl treatment generated the
HCl salt of the desired target (77) (Scheme 13).
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Recently, Zhao et al. reported a series of indolyl chalcones that can inhibit lung cancer cell growth.
Of all the derivatives tested, they found compound 78 (Figure 11) to be effective in the induction of
tumor apoptosis. It inhibited the growth of A549 cells by increasing the reactive oxygen species (ROS)
levels and by activation of the The nuclear factor erythroid 2–related factor 2 (Nrf-2) pathway [102].
In the in vivo studies, compound 78 exhibited anti-growth activity of the tumor in an avian embryo
model, showing the potential of the compound as the Nrf-2 activator in cancer therapy.
Hu et al. synthesized a series of indole derivatives with varying substituents at 2 and 5 positions.
The resulting compounds exhibited excellent anti-proliferative activity on lung cancer cell lines (H460
and A549) (Figure 11). Notably, compound 79a exhibited a high level of potency against A549 cells,
with the IC50 value of 0.50 ± 0.06 µM, while compounds 79b and 79c exhibited IC50 values of 0.16
± 0.05 µM and 0.48 ± 0.05 µM, respectively. Further detailed studies revealed that the compounds
induced apoptosis by he inhibition of phosphorylation of Ser2 of t e carboxyl-termi al domain of
RNA polymerase II, where RNA polymerase II is essential f r messenger RNA (mRNA) synthesis [103].
Huang et al. further identified a novel indole derivative, SK228 that can effectively inhibit lung
can er cell lines by ROS production a d induce cell death by apoptosis. To evaluate the potency of
SK228 gainst various human cancer cell lines, the authors tr ated he cells with ar ing concentrations
Molecules 2020, 25, 1615 17 of 25
of SK228 for 48 h. The resulting IC50 values were found to be 3.4 and 0.3 µM for A549 and H1299
cells respectively [104,105]. Further investigation of the mechanism of action showed that SK228
enhanced mitochondrial ROS production and inflicted DNA damage on cancer cells, ultimately leading
to intrinsic mitochondria-dependent mitosis.
SK228 was synthesized in a single step, as shown in Scheme 14 [105]. A mixture of
terephthalaldehyde (80) and 5-hydroxy-indole (81) in the presence of iodine afforded the desired
tetraindoles product (SK228).
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Liu et al. reported a novel indolyl quinoline moiety 3-((7- ethyl-1H-indol-3-yl)-
methyl)-2-methyl-quinoline (EMMQ) that can arrest cell-growth in NSCLC (A549 and H460) cells
(Figure 12). Cell growth inhibition studies after 48 h of dose-dependent treatment indicated EMMQ
IC50 values of 8 µM in both the A549 and H460 cell lines. This process involved the disruption of the
mitochondrial membrane potential, DNA damage and ultimately apoptotic cell death [107].
To note, tambjamines are indole based marine alkaloids, known to be highly efficient
transmembrane anion transporters in the model liposomes. They have widespread pharmacological
applications (Figure 12). Studies have shown that these alkaloids can induce apoptosis in several
cancer cell lines, rendering IC50 values in the micromolar range. Manresa et al. reported highly active
indole based tambjamine derivatives, investigating their molecular mechanism of action. The results
revealed that compounds 82 and 83 can induce apoptosis in lung cancer cells, in both in vitro and
in vivo studies. Cytotoxicity is induced by the ROS activated stress kinase pathway. This occurs
through the activation of P38 mitogen-activated protein kinase [108,109].
Evodiamine is an indole-containing alkaloid, isolated from a Chinese medicinal herb Evodia
rutaecarpa (Wu-Chu-Yu). It has numerous pharmacological applications such as anti-inflammatory,
Molecules 2020, 25, 1615 18 of 25
anti-obesity, anti-viral, anti-tumor, and anti-nociceptive effects (Scheme 15). Studies have shown that
evodiamine is capable of strong anti-tumor and cytotoxic activity against various human cancer cell
lines (gastric, colon, liver, lung, and breast). Detailed mechanistic studies by Zou et al. revealed that
evodiamine can exert the anti-tumor activity by the inhibition of Metadherin, which was identified
as a novel oncogene that is overexpressed in many tumor malignancies [110]. Zou and his team
demonstrated that the treatment of NSCLC cells (A549) with evodiamine results in an increased level of
Bax expression. This is followed by a decrease of Bcl-2 and MTDH, which substantiated the apoptotic
mechanism of action [111–113].
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Evodiamine was synthesized as shown in Scheme 15 [114]. The reaction of tryptamine (48) with
N-methylisatoic anhydride (84) in the presence of trifluoroacetic anhydride, 1,4-diazabicyclo[2.2.
2]octane (DABCO), triethoxymethane, and dimethylacetamide afforded the desired product of
evodiamine (Scheme 15).
An indole based alkaloid, Eudistomin K isolated from the Caribbean ascidian Eudistoma olivaceum
was found to be potent against human lung cancer (A-549) cell lines. It is reported to inhibit the P-388
tumor cell line with IC50 of 0.01 µg/mL (Figure 13) [115].
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Figure 13. Structures of eudistomin K, villalstonine, compounds 85, 86 and 87.
Bisindolylalkanes comprise two monomeric indole alkaloid units, derived from several natural
terrestrial and marine sources. They are known for their biological, pharmacological, and medicinal
properties. Villalstonine is derived from the Alstonia species, which is commonly found in the tropical
and subtropical regions. It was evaluated for its anti-cancer activity against human NSCLC cell
lines, adenocarcinoma (MOR-P), and large cell carcinoma (COR-L23) cell lines. Villalstonine was
demonstrated to be potent in cytotoxic activity with IC50 of 5 µM and 2.5 µM in MOR-P and COR-L23
cells, respectively (Figure 13) [116].
Ji et al. reported a novel class of indole-2-carboxylate derivatives, evaluating their anti-cancer
activity. They found that some compounds exhibited excellent anti-proliferative activity against
HepG2, A549, and MCF7 cells. Most importantly, compounds 85 and 86 showed more potency than
etoposide and pyrroloquinoline quinone drugs with IC50 ranging from 3.4 to 24 µM (Figure 13).
When compounds 85 and 86 were subjected to a Western blot analysis of poly ADP ribose polymerase
(PARP), both compounds triggered ROS production and induced PARP cleavage in A549 cells.
This study was done in a dose-dependent manner, indicating the induction of apoptosis. The results
showed that these substances can be promising lead compounds for the development of anti-lung
cancer drugs [117].
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Skouta et al. designed and synthesized a series of tetrahydro-β-carbolines derivatives.
These compounds were tested for their efficacy against a variety of human cancer cell lines, including
the lung cancer cells (H1299). They found that derivatives of tetrahydro-ß-carboline and barbituric
acid moieties with no spacer showed modest activity with LC50 of 32.8 µM in the H1299 cell lines.
Those analogs with a carbon spacer were either weakly active or non-selective. Compound 87 was
found to be the most potent than any of the derivatives. It was observed to induce caspase-independent
cell death selectively in cancerous cells [118].
3. Conclusions
Overall, indole based compounds have emerged as a powerful probe for scientists in the ongoing
battle against such life-threatening diseases, such as lung cancer. Significant advances in this area
are evidenced in the number of indole-based compounds entering the pre-clinical and clinical stages.
More advances are expected to meet the challenges associated with the accompanying chemotherapy.
With a better understanding of the drug resistance mechanism in lung cancer patients, coupled with
the multi-drug therapy advances offered by the indole-based derivatives, better and more promising
strategies for combatting lung cancer can be expected in the near future.
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